Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm

Apple

American Express

Bank of America

Carlisle Companies

Chevron

Kraft Heinz

Coca-Cola

L3Harris

Schwab US Dividend Equity ETF

Vanguard Dividend Appreciation ETF

This year, so far, dividend investors are dealing with underperformance as the market has shifted from value to growth stocks. This is amplified by economic growth fears. While underperformance isn't fun, weakness comes with opportunities, which is why I have aggressively added to a number of Buffett-style dividend growth stocks.

Buy-Alert: 3 Undervalued Buffett-Style Dividend Gems I'm Buying

Thanks to its business model, Danaher has managed to reach operational excellence. Solid tailwinds will back up the company to continue its compounding path.

Danaher: A Great Chance To Buy This Long-Term Compounder

Catalent

Vornado Realty Trust

Wynn Resorts

Earnings season has been better than feared, and we highlight two firms offering differing views on the state of the economy. There's also one falling Pharma company that (once again) delayed its Q3 results.

The Great Dividend Divide: Spotting Clues From 2 Telling Companies' Payout Changes

DxI 9000 Access Immunoassay Analyzer Boasts Industry's Highest Throughput per Footprint: Up To 215 Tests/Hour/Square Meter Innovations Bolster Assay Performance and Laboratory Productivity with New Analyte Processing and Detection Technology, Precision Sensors, Smart Algorithms, Remote Real-Time System Monitoring, and is the Only Immunoassay Analyzer with No Daily Maintenance i NT-proBNP Assay Now Available with Age-Based Cutoffs and Comorbidity Data ROME , May 15, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).

Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance

Danaher Corp. ( DHR , Financial) is planning to spin off another piece of its conglomerate. Could this be an opportunity for investors, especially considering its share price has been in decline?

Danaher: A Long-Term Prospect With a Potential Bonus

Danaher Corporation (NYSE:DHR ) Bank of America Securities 2023 Healthcare Conference May 10, 2023 1:00 PM ET Company Participants Mike Ryskin - Analyst, Bank of America Life Science Tools and Diagnostics Team Rainer Blair - Chief Executive Officer, Danaher Corporation Conference Call Participants Mike Ryskin Thank you for joining us for our next session. For those of you that don't know me, I'm Mike Ryskin on the Bank of America Life Science Tools and Diagnostics team with Co-Senior Analyst, Derik De Bruin.

Danaher Corporation (DHR) Bank of America Securities 2023 Healthcare Conference Transcript

LOS ANGELES, CA / ACCESSWIRE / May 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm

NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Danaher Corporation ("Danaher" or the "Company") (NYSE: DHR). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Danaher Corporation - DHR

LOS ANGELES, CA / ACCESSWIRE / May 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm

Applied Materials

Amgen

Home Depot

Jacobs Solutions Inc

Lowe's

Lam Research

NIKE

Paychex

Progressive

Raymond James

Stryker

Warren Buffett held court again at Berkshire Hathaway's shareholder meeting. But his company could learn from some other S&P 500 companies.

16 Stocks Run Circles Around Warren Buffett Over The Long Haul

AutoNation

Ecolab

It's been a good year for Bill Gates. According to the Bloomberg Billionaires Index , the Microsoft (NASDAQ: MSFT ) co-founder's net worth is up $15.5 billion to $125 billion.

What Does Bill Gates Know That You Don't? 3 Stocks He Is Buying.

WASHINGTON , May 3, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 10:00 a.m.

Danaher to Present at Bank of America Securities Health Care Conference

Agilent Technologies

Amphenol

Corning

Keysight

QUALCOMM

Waters

Jefferies analyst Desh Peramunetilleke says cheap stocks set to benefit from China's rebound include Keysight, Qualcomm, Agilent, Danaher, and Corning.

China-Exposed Stocks Have Rallied, but Bargains Still Exist, Says Analyst

Will offer mRNA cGMP Production   from Master Cell Bank to Drug Product Made Possible with Precision Nanosystems and Cytiva   FARGO, N.D. , May 1, 2023 /PRNewswire/ -- Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from Master Cell Bank through to Drug Product.

ALDEVRON ANNOUNCES EXPANSION OF mRNA PRODUCTION CAPABILITY

Roper Technologies

Essential Utilities

If you're interested in investing in water tech stocks, you'd be wise to turn to Invesco. It's cornered the market on water technology companies, marketing three of the top water exchange-traded funds (ETFs) listed on U.S. stock exchanges: Invesco Water Resources ETF (NASDAQ: PHO ), Invesco S&P Global Water Index ETF (NYSEARCA: CGW ) and Invesco Global Water ETF (NASDAQ: PIO ).

3 Innovative Water Tech Stocks to Watch in a Thirsty World

Abbott Labs

Intuitive Surgical

McKesson

Eli Lilly

Moderna

UnitedHealth Group

Healthcare stocks are one of the best bets out there. The U.S. spends more on healthcare than any other country.

7 Healthcare Stocks With Huge Return Potential for Long-Term Investors

LOS ANGELES--(BUSINESS WIRE)---- $DHR #DHR--The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Danaher Corporation and Encourages Investors with Losses to Contact the Firm

Danaher's (DHR) Q1 earnings and revenues beat estimates. However, a decline in the sale of COVID-related products weigh on the top line.

Danaher (DHR) Q1 Earnings Beat, Revenues Decline 7% Y/Y

Markets fell on Tuesday amid worries about a possible recession. United Parcel Service saw drops in shipping volume that hit sales and earnings.

These 2 Large-Cap Laggards Are Leading Markets Lower Tuesday

Danaher Corporation (DHR) Q1 2023 Earnings Call Transcript.

Danaher Corporation (DHR) Q1 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Danaher (DHR) Q1 Earnings: A Look at Key Metrics

WASHINGTON , April 25, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2023.  Net earnings refer to net earnings attributable to common shareholders.

Danaher Reports First Quarter 2023 Results

Clearpoint Neuro Inc

Charles River Laboratories

It's been a rocky market for growth stocks over the past 18 months. We've seen a flurry of layoffs and spending cutbacks from leading tech companies.

News for Danaher Stock (DHR)